The latest research: Wegovy is also effective for patients with diabetes and heart failure
嫦娥的情人矩
发表于 2024-4-7 10:32:07
1248
0
0
A new study shows that Wegovy (mainly composed of smeglutide), the "weight-loss magic drug" of Novo Nordisk, can not only lose weight, but also benefit the health of patients with diabetes and heart failure.
This report, published on Saturday (April 6th) in the medical journal New England Journal of Medicine, stated that for heart failure patients, especially those with preserved ejection fraction (HFpEF) associated with obesity, receiving Wegovy treatment resulted in more significant weight loss and lower incidence of serious adverse events.
This type of heart failure severely limits a person's ability to participate in daily life, and patients are often prone to fatigue, breathing difficulties, which can lead to a high risk of hospitalization, disability, and death.
At present, the methods for treating HFpEF include lifestyle changes and heart disease drugs, but there is no specifically approved treatment for HFpEF, and the number of people suffering from this disease has been significantly increasing.
Last fall, researchers released a study that showed that Wegovy had a significant positive health effect on people with this heart disease, but later they wanted to see whether Wegovy also had an effect on patients with type 2 diabetes and HFpEF.
In the latest study, 616 patients with type 2 diabetes and HFpEF were randomly divided into two groups. The patients come from 16 countries and their body mass index (BMI) is above 30. One group takes Wegovy, and the other group takes a placebo.
Researchers conducted a one-year follow-up survey on two groups of patients. The conclusion is that patients receiving Wegovy treatment have significantly better effects on weight loss, heart failure related symptoms, and physical limitations compared to those taking placebo. In addition, these patients were able to walk further in the six minute walk test and showed improvement in biomarkers for inflammation and other issues.
In terms of adverse events, the Wegovy treatment group reported 55 severe adverse events, while the placebo group reported 88 cases. In terms of the number of deaths, there were 6 deaths in the Wegovy group and 10 deaths in the placebo group, with 1 death related to cardiovascular problems in the Wegovy group and 4 deaths in the placebo group.
Dr. Mikhail Kosiborod, a researcher and cardiologist at the Central American Heart Institute in Saint Luke, said that the consistent results of the latest research and the research published last year seemed to indicate that Wegovy was an effective and safe treatment option for a wide range of people, including diabetes patients.
On Saturday, Kosiborod also introduced the study to the American College of Cardiology, and he found it very exciting because heart failure patients are usually difficult to treat, and the number of such patients is constantly increasing. But now, Wegovy has not only shown therapeutic efficacy, but also good tolerability, which means patients can withstand this treatment well without serious side effects.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Smeaglutide tablet for type 2 diabetes was approved for marketing in China
- Oral smeglutide is approved to be marketed in China for the treatment of type 2 diabetes
- Li Xiande from Jingke Energy: Maintain strategic patience during the industry's lowest period of downturn. Unprofitable production capacity will be quickly phased out
- Federal Reserve Governor Waller: Stay patient with interest rate cuts, wait for more data!
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
- Abbott: Science and technology enable daily management of diabetes, stable and accurate, and protect blood sugar health
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
-
2024年11月7日,由新华社新闻信息中心、新华社上海分社、新华社品牌工作办公室主办的“品牌·让世界更美好”中外品牌论坛在上海举办。此次论坛,理想汽车荣获“通用ESG企业评价规范”年度最佳品牌奖。理想汽车将 ...
- cool88817
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
【别跟我提特朗普!鲍威尔发布会:无需过度解读措辞改变 民众“不觉得经济好”没错】北京时间周五凌晨3点30分,美联储主席鲍威尔举行新闻发布会,就继续降息25个基点的决定和市场热点话题回答全球媒体提问。鲍威尔在 ...
- anhao007
- 半小时前
- 支持
- 反对
- 回复
- 收藏
-
何思文表示,“在进博会这个平台上,我们开启的是倾听模式,通过进博会展出各类产品,收集消费者的需求和反馈,进而帮助决定未来进口到中国的产品。过去,汽车行业的许多创新源于美国加州或欧洲。我相信,中国正 ...
- MaxLucky
- 11 小时前
- 支持
- 反对
- 回复
- 收藏
-
11月5日至10日,第七届中国国际进口博览会(下称“进博会”)在国家会展中心(上海)举办。在进博会期间,平安健康医疗科技有限公司(下称“平安健康”)与美敦力(上海)管理有限公司(下称“美敦力”)达成战 ...
- Hidden2
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏